AR SB913

Requires that mifepristone (RU-486) or other abortion-inducing drugs be administered in the same room and physical presence of the prescribing physician

Mandates physician ensure patient returns 12-18 days after drug administration for follow-up visit to confirm pregnancy termination and assess medical condition, with documentation required in medical records

Authorizes licensing boards to revoke physician licenses upon finding violation of these requirements, with no penalties assessed against the pregnant woman

Allows civil lawsuits for actual and punitive damages by the pregnant woman, biological father (if married), or maternal grandparents against persons violating this section; permits prosecuting attorney to seek injunctive relief

Protects pregnant women from liability for obtaining or possessing abortion-inducing drugs for their own use and allows anonymity protection in court proceedings with sealing of records and pseudonym use by non-government plaintiffs